Therefore, PD-L1 blockade therapy reduced mTOR activity and mTOR–mediated upregulation of glycolysis in tumor cells, which, in turn allowing more available glucose within the extracellular milieu of the tumor and restores TILs glycolytic capacity and, as a result, their effector function (83). This evidence concerns the gene MTOR and neoplasm.